Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

News, archive: September 2020

9/29/2020 Survey by RNC Pharma and Doktor Na Rabote (Doctor at Work): 57% of Russian Doctors Say Healthcare Facilities not Ready for Rise in Coronavirus Cases

Only 11% of doctors say that healthcare facilities are fully prepared for a possible surge in the incidence of coronavirus infection, according to a survey by the RNC Pharma analyst company and the Doktor Na Rabote (Doctor at Work) social media service for doctors. It is interesting that as many as 19% of the respondents from Moscow and St. Petersburg and only 8% of those coming from other regions chose this answer.

9/18/2020 Database Update: Audit of Veterinary Drug Retail Sales in Russia (August 2020)

Between January and August 2020, the sales of veterinary drugs in the retail market amounted to RUB 14.3 bln (retail prices, VAT included), which is in monetary terms (rubles) hardly a hundredth of a percent higher than in 2019. The volume in physical terms is 125.1 bln minimum dosage units (MDU), which is 1.7% lower than in 2019.

9/10/2020 Pharmaceutical Drug Export from Russia (June and Q1 – Q2 2020)

Between January and June 2020, Russia exported RUB 23.2 bln worth of ready-made pharmaceutical drugs (customs duties included). This sum does not include Geropharm’s exports of insulins to Venezuela; while the company openly declares its exports, it does not reveal the volumes. The dynamics are +14.7% in monetary terms (rubles), which is significantly higher than those at the end of 2019 (+13%). The volume in physical terms exceeded 0.56 bln units, with the dynamics of +35%.

9/1/2020 Pharmaceutical Drug Production in Russia (July 2020)

Between January and July 2020, Russia produced 267.1 bln RUB worth of pharmaceutical drugs (manufacturer’s prices, VAT included), which is in monetary terms (rubles) 19.4% higher than in 2019. In physical terms, the production volume is 2.78 bln units, with the dynamics of +13.3%. If calculated in minimum dosage units (MDU), the dynamics are +19%, with the volume of 48.8 bln MDUs.